Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

This publication has 55 references indexed in Scilit:

• A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of ORG 2766 in the Prevention or Delay of Cisplatin-Induced Neuropathies in Women with Ovarian Cancer
  Gynecologic Oncology, 1997
• Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1995
• Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy
  Annals of Neurology, 1995
• Taxol protects against calcium-mediated death of differentiated rat pheochromocytoma cells
  Life Sciences, 1994
• Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)
  Anti-Cancer Drugs, 1994
• Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex
  European Journal Of Cancer, 1993
• Reducing Chemotherapy-Induced Nausea and Vomiting Current Perspectives and Future Possibilities
  Drug Safety, 1993
• Examination of distal involvement in cisplatin-induced neuropathy in man
  Brain, 1993
• Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
  New England Journal of Medicine, 1990
• Effects of the cytostatic drug cis‐platinum on the developing neocortex of the mouse
  Teratology, 1983